Human cibinetide evidence includes small exploratory studies with very different populations. A 22-person sarcoidosis-neuropathy pilot reported a symptom-score difference, while a 9-person diabetic-macular-edema study missed its principal ocular measures.
Evidence at a glance
- The randomized sarcoidosis pilot enrolled 22 participants: 12 received ARA-290 and 10 placebo.
- The SFNSL change at week 4 was −11.5 ± 3.04 versus −2.9 ± 3.34, while pain-intensity and fatigue scores improved similarly in both groups.
- In the DME study, 9 were enrolled and 8 completed; mean visual acuity, retinal thickness, retinal sensitivity and tear production did not improve.
Study record
The neuropathy pilot reported a statistically significant between-group change in the small-fiber-neuropathy screening list. However, Brief Pain Inventory and fatigue scores improved significantly but equivalently in both groups, and the depression inventory did not change.
Results in context
The 2020 diabetic-macular-edema study was even smaller. At 12 weeks, mean BCVA changed by −2.9 ± 5.0, central retinal thickness by 10 ± 94.6 µm and central retinal sensitivity by −0.53 ± 1.9 dB. A patient-reported visual-function composite improved by 2.7 ± 3.1, but the design was descriptive and uncontrolled.
Several DME-paper authors were officers, owners or consultants of the developer. That disclosure does not invalidate the results, but it belongs beside the data when readers judge a small exploratory trial.
What the evidence cannot establish
Small samples and short follow-up make effect estimates unstable.
Different diseases and endpoints cannot be combined into one broad “nerve repair” claim.
Neither study establishes equivalence to a catalog material or supports use outside research.
Sources & editorial method
The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, study size, model/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Randomized ARA-290 sarcoidosis-neuropathy pilotPrimary exploratory trial; PMID 23168581.
- Phase 2 clinical trial of cibinetide for diabetic macular edemaClinical Ophthalmology. 2020. PMID 32674280.
- PubChem Cibinetide recordSequence, synonyms, formula and mass; CID 91810664.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
